{"product_id":"ck-lifesciences-pestle-analysis","title":"CK Life Sciences Int’l. PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic edge with our PESTLE analysis of CK Life Sciences Int’l., revealing how political, economic, social, technological, legal and environmental forces shape its prospects. Actionable insights identify risks and growth levers for investors and strategists. Purchase the full report to access the complete, downloadable breakdown and turn insight into impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approval landscapes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory approval timelines differ widely: US FDA standard review targets 10 months (6 months priority), EMA centralized review ~210 days, and China NMPA median review ~12 months; ASEAN national registrations often add 18–36 months. Alignment with Hong Kong, Mainland China, US, EU, and ASEAN regulators is critical: China’s pharma market was about $198B in 2024 and ASEAN ~$43B, so policy shifts that speed or delay trials, imports, and market access materially affect time-to-market; proactive regulator engagement reduces uncertainty and shortens launch timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare and agricultural policy priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment funding and incentives under national plans (eg China’s 14th Five-Year Plan 2021–25) boost biotech, food-security and preventive health demand, with public procurement often privileging local crop and health innovations. WHO estimates malnutrition contributes to about 45% of child deaths, underpinning large public nutrition programs that expand addressable markets. Policy reversals or subsidy cuts can rapidly reduce revenue visibility for CK Life Sciences.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical trade and supply-chain exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCK Life Sciences faces tariffs up to 25% and tightening export controls that raise costs for inputs, reagents and cross‑border sales; global container freight rates, which plunged ~70% from 2021 to 2023, show volatility but disruptions persist. China–US\/EU tensions risk biotech collaboration and data sharing, while diversified sourcing and regional manufacturing reduce interruption risk. Diplomatic shifts can rapidly unlock or constrain licensing and JV opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic R\u0026amp;D funding and partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic R\u0026amp;D funding and university partnerships lower CK Life Sciences’ marginal R\u0026amp;D costs and increase innovation throughput by enabling access to shared facilities, talent pipelines and translational grants; national biotech roadmaps in China and Hong Kong shape research focus and clinical priorities, aligning company pipelines with public health targets. Participation in multi‑institution consortia speeds validation and adoption, while funding cycles and election outcomes affect program continuity and milestone timing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to grants and university ties: reduces capex and time-to-proof\u003c\/li\u003e\n\u003cli\u003eNational biotech roadmaps: align pipeline priorities\u003c\/li\u003e\n\u003cli\u003eConsortia participation: accelerates validation\/adoption\u003c\/li\u003e\n\u003cli\u003eFunding cycles\/elections: drive continuity risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFood and biosecurity oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStricter GMO, pesticide and biohazard controls force CK Life Sciences to redesign products and extend testing timelines, increasing R\u0026amp;D and regulatory costs.\u003c\/p\u003e\n\u003cp\u003ePhytosanitary rules shape registration and exports, especially under international frameworks such as the Cartagena Protocol (173 Parties as of 2024), affecting market access.\u003c\/p\u003e\n\u003cp\u003eRobust compliance enhances credibility with regulators and farmers, while breaches risk bans, fines and lasting reputational damage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory redesign: higher R\u0026amp;D\/testing costs\u003c\/li\u003e\n\u003cli\u003eMarket access: influenced by 173‑party Cartagena Protocol (2024)\u003c\/li\u003e\n\u003cli\u003eCompliance = credibility with regulators\/farmers\u003c\/li\u003e\n\u003cli\u003eNon-compliance = bans, fines, reputational loss\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory timelines, tariffs and geopolitics reshape pharma time-to-market and revenues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory timelines (US FDA 10 months\/6 priority; EMA ~210 days; China NMPA ~12 months) and market size (China pharma $198B 2024; ASEAN ~$43B) critically affect CK Life Sciences’ time‑to‑market and revenues. Tariffs\/export controls, China–US\/EU tensions and Cartagena (173 parties, 2024) shape access, costs and JV\/licensing opportunities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review\u003c\/td\u003e\n\u003ctd\u003e10 mo (6 priority)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMA review\u003c\/td\u003e\n\u003ctd\u003e~210 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMPA review\u003c\/td\u003e\n\u003ctd\u003e~12 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina pharma market\u003c\/td\u003e\n\u003ctd\u003e$198B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASEAN market\u003c\/td\u003e\n\u003ctd\u003e$43B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCartagena signatories\u003c\/td\u003e\n\u003ctd\u003e173 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect CK Life Sciences Int’l across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and forward-looking insights to support executives, investors, and strategists with actionable risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary of CK Life Sciences Int’l. that’s easily dropped into presentations, shared across teams, and annotated for local context—helping streamline external risk discussions and accelerate strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacro growth and consumer spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAsia-Pacific GDP cycles—China growth 5.2% and India 6.8% in 2024 (IMF)—directly drive demand for nutraceuticals and healthcare products, boosting volume in expansion phases.\u003c\/p\u003e\n\u003cp\u003eRising incomes support premium wellness categories, while episodic slowdowns push consumers toward value offerings and generics.\u003c\/p\u003e\n\u003cp\u003eCK Life Sciences should flex its portfolio mix between premium and value lines in line with consumer sentiment and regional GDP signals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing, reimbursement, and farmer economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDrug pricing and insurance coverage drive clinical uptake and time-to-market for CK Life Sciences' therapeutics, while farm input affordability hinges on crop prices and credit access; the World Bank fertilizer price index fell about 30% from the 2022 peak to 2024, easing input costs for growers. Demonstrated ROI is vital for agricultural adoption, and value‑based propositions can materially reduce customer churn during downcycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFX, interest rates, and capital costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue and cost currencies for CK Life Sciences can diverge across R\u0026amp;D (often USD\/EUR), manufacturing (USD\/CNY) and sales hubs (HKD pegged to USD within the 7.75–7.85 band), creating FX translation risk. US policy rates around 5.25–5.50% (July 2025) lift discount rates, raising WACC and compressing DCF valuations for pipelines. Active hedging of FX and interest exposure stabilises margins and capex plans. Sharp volatility can materially reprice licensing deals and M\u0026amp;A premiums.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInput costs and bioprocess efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising inflation and episodic scarcity pushed bioreactor media, APIs and specialty chemicals up roughly 12–18% between 2021–2024, tightening CK Life Sciences’ input cost base.\u003c\/p\u003e\n\u003cp\u003eEven modest yield gains materially expand gross margins in biologics: industry data show CMO utilization near 80–85% in 2023–24, making yield improvements highly leverageable.\u003c\/p\u003e\n\u003cp\u003eContract manufacturing rates swing with capacity cycles, while multi‑year supply contracts have been shown to cut unit cost volatility and procurement spend by double digits.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInput inflation: 12–18% (2021–2024)\u003c\/li\u003e\n\u003cli\u003eCMO utilization: ~80–85% (2023–2024)\u003c\/li\u003e\n\u003cli\u003eYield sensitivity: direct gross‑margin leverage\u003c\/li\u003e\n\u003cli\u003eLong‑term contracts: reduce unit cost volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket structure and competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCK Life Sciences faces intensified price pressure from big pharma, large generics and agri-input majors driving commoditization; the global generics market was roughly $300–350bn in 2024 and agrochemicals saw 5–10% annual price deflation in key segments. Strong IP and clinically superior efficacy allow premium pricing—top-tier biologics still command \u0026gt;30% price premiums. Ongoing consolidation shifts channel bargaining power toward larger distributors, while niche R\u0026amp;D focus sustains margins in crowded markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: generics ~300–350bn (2024)\u003c\/li\u003e\n\u003cli\u003ePrice pressure: agrochemical deflation 5–10% pa\u003c\/li\u003e\n\u003cli\u003ePremiums: biologics \u0026gt;30% price premium\u003c\/li\u003e\n\u003cli\u003eStrategy: niche\/IP protects margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory timelines, tariffs and geopolitics reshape pharma time-to-market and revenues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAsia‑Pacific GDP (China 5.2%, India 6.8% in 2024) drives nutraceutical demand; CKLS should shift between premium and value lines with GDP signals.\u003c\/p\u003e\n\u003cp\u003eInput inflation rose 12–18% (2021–24) while fertilizer prices fell ~30% (2022–24), easing some agri costs; CMO utilization ~80–85% (2023–24) magnifies yield gains.\u003c\/p\u003e\n\u003cp\u003eUS rates 5.25–5.50% (Jul 2025) raise WACC, FX and interest hedging critical; global generics ~$300–350bn (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina GDP 2024\u003c\/td\u003e\n\u003ctd\u003e5.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia GDP 2024\u003c\/td\u003e\n\u003ctd\u003e6.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput inflation (2021–24)\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFertilizer index change\u003c\/td\u003e\n\u003ctd\u003e−30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO utilization\u003c\/td\u003e\n\u003ctd\u003e80–85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS policy rate (Jul 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics market 2024\u003c\/td\u003e\n\u003ctd\u003e$300–350bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eCK Life Sciences Int’l. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview of the CK Life Sciences Int’l. PESTLE Analysis is the exact document you’ll receive after purchase. It’s fully formatted, professionally structured, and ready to use. The content and layout shown here are identical to the file available for instant download after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162532458873,"sku":"ck-lifesciences-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/ck-lifesciences-pestle-analysis.png?v=1762702524","url":"https:\/\/portersfiveforce.com\/products\/ck-lifesciences-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}